Avsnitt
-
In this episode, Prof. Hindrik Mulder, Editor-in-Chief of Diabetologia, joins us to discuss the journals accomplishments over the past year and its vision for the future of diabetes research. From embracing AI in research processes to addressing global health disparities, Prof. Mulder highlights how Diabetologia remains at the forefront of the field.
He also shares his excitement about advancements in stem-cell and beta-cell research, the potential of precision medicine, and the role of incretin-based therapies, Prof. Mulder previews Diabetologia's special symposium on technology in diabetes care, co-created with patients, and explores how collaborative efforts are driving innovation in treatment and care.
Join us for this inspiring conversation about the future of diabetes research and care. -
In this episode, Prof. Frank Tacke (Charité – Universitätsmedizin Berlin), Prof. Michael Roden (University of Düsseldorf), and Prof. Hannele Yki-Järvinen (University of Helsinki) discuss the groundbreaking new guidelines for metabolic dysfunction-associated steatotic liver disease (MASLD).
The episode explores the shift from the term "NASH" to MASLD, addressing the rationale behind this change and its implications for reducing stigma and improving diagnosis. The experts delve into innovative diagnostic tools, such as FIB-4 and transient elastography, and the evolving role of GLP-1 receptor agonists and emerging liver-specific therapies.
Join us to learn how multidisciplinary collaboration between hepatologists, diabetologists, and obesity specialists is reshaping the approach to managing liver disease in people with diabetes. -
Saknas det avsnitt?
-
In this episode, we explore the vital role of National and European diabetes forums, respectively, in shaping policies and improving care for people living with diabetes. Featuring Bogdan Timor (Romanian Diabetes Forum) and Frank Nobels (Belgian Diabetes Forum), the discussion highlights how collaborative efforts, and shared strategies can drive early detection, prevention, and better management of diabetes across Europe. From Romania's groundbreaking diabetes prevention law to Belgium's integrated care and data projects, this episode showcases the power of collective advocacy in transforming diabetes care.
-
In this episode, Aoife Egan and Daniel Morganstein discuss the complexities of managing glycaemic emergencies in special patient populations. From diabetic ketoacidosis (DKA) during pregnancy to hypoglycaemic crises triggered by cancer treatments, they explore the importance of multidisciplinary collaboration, education, and awareness in delivering timely and effective care.
-
QWINT: A Paradigm Shift in Insulin Therapy
In this episode, Harpreet Bajaj, Carol Wysham, and Richard Bergenstal explore the revolutionary QWINT program, a once-weekly insulin therapy currently in development. With a unique mechanism of action resulting in a 17-day half-life, QWINT has the potential to transform diabetes care by reducing the treatment burden for patients and caregivers alike.
The discussion covers key findings from the program’s trials, including strong patient preference despite challenges in type 1 diabetes management, and highlights the benefits for older patients and those requiring assistance with daily activities. Join us to learn how QWINT is poised to redefine insulin therapy and improve the quality of life for people living with diabetes. -
In this first episode of the year, our very own president Prof. Chantal Mathieu and other leading experts explore the future of type 1 diabetes. Join Vivienne Parry as she sits down with renowned experts - EASD President Prof. Chantal Mathieu, Dr. Peter Rossing, and Dr. Rory McCrimmon - to discuss the future of type 1 diabetes.
From global screening initiatives to cutting-edge research on islet transplantation and organ protection, this conversation highlights how far we've come - and the exciting journey ahead!
Tune in for insights from experts dedicated to improving lives through groundbreaking research and solutions. -
In this episode, Dr Elisa De Franco, recipient of the 2024 EASD Minkowski Award, takes us on a journey through her groundbreaking research into neonatal diabetes. Dr De Franco’s work has revolutionised the understanding and treatment of this rare form of diabetes, diagnosed in babies under six months old. From identifying 10 - 15 genetic mutations linked to neonatal diabetes to shedding light on beta cell biology, Elisa’s discoveries are transforming lives and advancing diabetes research.
Join us to explore the global impact of Exeter's diagnostic service, the role of next-generation sequencing in genetic research, and how rare genetic mutations provide vital insights into type 1 and type 2 diabetes. She also shares a glimpse of her Minkowski Lecture, offering exciting discoveries that highlight the power of genetics in medicine. -
Adipose tissue isn't just "fat" - it's a remarkable endocrine organ with transformative impacts on health and diabetes. In this episode, discover groundbreaking insights from Dr Alice Williamson of Queen Mary University, London, and Dr Lori Goodyear of Harvard Medical School.
Learn about the genetic factors behind insulin resistance and the revolutionary role of exercise in remodelling adipose tissue. From genetic breakthroughs to potential therapies, this discussion unpacks the future of diabetes care. Find out why fat is more than just a roll around your middle - it’s a key player in metabolic health! -
In this episode, Alice Rickford and Andrzej Kokoszka discuss the complex challenges of managing diabetes in disadvantaged communities and among individuals with mental health conditions. Alice Rickford, a healthcare professional from London, highlights barriers like homelessness, access to care, and the stigma faced by people living with diabetes in vulnerable situations. Andrzej Kokoszka, from Poland, sheds light on the relationship between mental health and diabetes, focusing on depression, body image issues, and the role of self-management. The conversation offers practical advice for clinicians, emphasizing the need for a holistic, patient-centred approach to care, and how building trust and providing emotional support are key to improving patient outcomes.
-
In Episode 3 of our podcast, experts from Argentina, Mexico, Pakistan, and Sri Lanka share a comprehensive view of the diabetes epidemic in their countries. The conversation highlights the alarming rise in diabetes and pre-diabetes cases, touching on the challenges faced by their healthcare systems and the urgent need for government intervention. Dr. Prasad Katulanda (Sri Lanka) discusses the exponential growth in diabetes rates, while Dr. Abdul Basit (Pakistan) talks about the push for government action and better healthcare funding. Dr. Javier Farias (Argentina) and Dr. Leonardo Mancillas (Mexico) also share the growing concern over obesity and the steps their countries are taking to address it through public policy, prevention programmes, and healthcare reform.
-
Episode 2 features Matthias Blüher and Anette Ziegler, two leading experts in diabetes research, as they share their insights into the future of diabetes care by 2030. The conversation explores innovative developments in the prevention and treatment of both Type 1 and Type 2 diabetes, with a focus on early diagnosis, immune interventions, and the potential of incretin-based therapies. Dr. Blüher discusses the exciting possibilities of personalised medicine and new pharmacotherapies, while Dr. Ziegler emphasizes the importance of primary prevention and the latest research into viral triggers. This episode delves into the evolving landscape of diabetes care and the potential to revolutionise treatment options in the next decade.
-
Our first episode features Dr. Roy Taylor, a leading diabetes researcher and recipient of the prestigious EASD Claude Bernard Prize, discussing groundbreaking insights into type 2 diabetes remission. He shares his journey in proving that type 2 diabetes can, in many cases, be reversed through targeted weight loss to reduce fat in the liver and pancreas. Dr. Taylor recounts the challenges he faced in gaining acceptance for his theories and highlights the role of media and patient stories in spreading awareness. His approach has influenced a shift in treatment options, including the development of a national programme in the NHS for diabetes remission.
